Comparison of AmnioFix Laser and Standard of Care Treatment

Sponsor
University of California, San Francisco (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02659124
Collaborator
(none)
0
1
1

Study Details

Study Description

Brief Summary

This is a comparison trial with novel application of AmnioFix and a control arm. Patients electively being treated with facial lasers will be assigned to receive AmnioFix in addition to the normal standard of care placed on half of their face after laser procedure, and normal post laser standard of care alone on the other half of their face. The investigators will investigate the end points of healing, recovery time, re-epitheliaziation, and other cosmetic factors. The study is designed to compare AmnioFix to the current standard of laser care.

Condition or Disease Intervention/Treatment Phase
  • Device: AmnioFix plus Standard of Care
  • Procedure: Standard of Care
N/A

Detailed Description

AmnioFix is a dehydrated Human Amnion/ Chorion Membrane (dHACM) allograft and is composed of multiple layers including a single layer of epithelial cells, a basement membrane and an avascular connective tissue matrix. Amniotic membrane is a unique material and its composition contains collagen types I, III, IV, V, and VII. Amniotic membrane is composed of structural extracellular matrix (ECM), that also contains specialized proteins fibronectin, laminins, proteoglycans and glycosaminoglycans. In addition, amniotic membrane contains essential, active, healing growth factors such as epidermal growth factor (EGF), transforming growth factor beta (TGF-b), fibroblast growth factor (FGF), and platelet derived growth factor (PDGF).

The study is designed to compare AmnioFix to the current standard of laser care.

  • Patients coming in for fraction or total ablative resurfacing with any methods will be studied

  • patients will be assessed prior to any treatment by clinician

  • additionally patients will participate in a clinician constructed survey

  • patients will be assessed on a rating scale of 1-4 based on erythema, edema/induration, oozing/drainage, and epithelialization

  • preoperative photos will be taken of patients

  • laser resurfacing will proceed under clinician guidance, and under clinician selected settings

  • repeat photographs

  • patients will be randomized as to which side of the face receives AmnioFix treatment, and which side receives standard of care

  • epifix will be applied appropriatly

  • repeat photographs and repeat assessment on 1-4 scale

  • patients will follow up at day 1, 4, 7, 14, and 28 +/-3 days to repeat scoring and photography

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Comparison of AmnioFix Laser and Standard of Care in Patients Seeking Laser Facial Treatment
Anticipated Primary Completion Date :
Apr 1, 2017
Anticipated Study Completion Date :
Jan 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Other: Standard of Care plus AmnioFix

All patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face.

Device: AmnioFix plus Standard of Care
Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.

Procedure: Standard of Care
Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.

Outcome Measures

Primary Outcome Measures

  1. Time of reepithelialization [28 days after treatment]

    Subjects' healing and recovery is the primary outcome measure. Reepithelialization will be assessed at each follow up visit, considering the following: erythema, edema/induration, and oozing/drainage.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • adult patients ages 18-100 seeking laser facial treatment
Exclusion Criteria:
  • patients with treatment areas with active or latent infection

  • patient with a disorder that would create an unacceptable risk of post-operative complications

Contacts and Locations

Locations

Site City State Country Postal Code
1 UCSF Dermatology San Francisco California United States 94115

Sponsors and Collaborators

  • University of California, San Francisco

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT02659124
Other Study ID Numbers:
  • AmnioFix Laser Study
First Posted:
Jan 20, 2016
Last Update Posted:
Mar 21, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by University of California, San Francisco

Study Results

No Results Posted as of Mar 21, 2022